Corpus Intelligence IC Memo — ASOCIACION HOSPITAL DEL MAESTRO INC 2026-04-26 12:37 UTC
IC Memo — ASOCIACION HOSPITAL DEL MAESTRO INC
Investment Committee Memorandum | PR | 125 beds | Grade C | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ASOCIACION HOSPITAL DEL MAESTRO INC

CCN 400004 | nan, PR | 125 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ASOCIACION HOSPITAL DEL MAESTRO INC is a 125-bed safety-net/medicaid heavy in nan, PR with $16.3M in net patient revenue and a -17.6% operating margin. The hospital serves a payer mix of 9.3% Medicare, 32.9% Medicaid, and 57.8% commercial.

Thesis: Undervalued. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -17.6% to -10.3% (+736bps).

Net Revenue HCRIS$16.3M
Current EBITDA COMPUTED$-2.9M
Operating Margin COMPUTED-17.6%
Occupancy HCRIS30.5%
Revenue / Bed COMPUTED$130K
Net-to-Gross HCRIS57.8%
Distress Probability ML63.5%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
39
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -17.6% places it below the state median. Among 39 size-comparable peers (62-250 beds), the median margin is -8.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (62-250), prioritizing same-state peers. 39 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ASOCIACION HOSPITAL DEL MAESTR (Target)PR125$16.3M-17.6%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
ADMIN DE SERVICIOS MEDICOS DE PR65$179.7M-50.0%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%
UNIVERSITY DISCTRICT HOSPITALPR210$97.4M-43.2%
HOSPITAL MENONITA AIBONITOPR129$92.1M-3.1%
HOSPITAL DE LA CONCEPCIONPR167$91.0M-3.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$342K+210bp18mo
Cost to Collect4.5%2.5%$325K+200bp12mo
Denial Rate Reduction12.0%6.5%$322K+198bp12mo
A/R Days Reduction5200.0%3800.0%$198K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$342K
Cost to Collect
$325K
Denial Rate Reduction
$322K
A/R Days Reduction
$198K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.2M
Current EBITDA$-2.9M
+ RCM Uplift+$1.2M
Pro Forma EBITDA$-1.7M
Current Margin-17.6%
Pro Forma Margin-10.3%
WC Released (1x)$624K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.4M$-7.0M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.4M$-9.1M0.00x-100.0%
Bull Case9.0x11.0x$-4.0M$-6.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-4.0M$-8.3M0.00x-100.0%
Bear Case11.0x10.0x$-4.9M$-11.5M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.9M$-14.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (32.9%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
MediumLow occupancyAt 30.5%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 63.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 39 hospitals with 62-250 beds
  • Same-state prioritization (n=40)
  • Comp margins: P25=-20.7% / P50=-8.2% / P75=0.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.